PositiveToplineResults (@PositiveTopline) profile picture

PositiveToplineResults

@PositiveTopline

I don't know anything (not very smart). May or may not have positions in stocks I mention. Likes are bookmarks only.

 Somewhere / Nowhere
Joined February 2021
  • Tweets868
  • Following375
  • Followers713
128Media
Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)Photo by PositiveToplineResults (@PositiveTopline)
Nothing says attention to detail quite like presenting obicetrapib data in a poster saved as "Sonidegib Duration of Response (DOR) at 30 Months: Results from the Phase 2 BOLT Trial" $NAMS
1
8
1,476
You guys blind? Clearly works in >90 md/dL between months 24-30. Gl $amgn $LLY
Image from PositiveToplineResults (@PositiveTopline)
Adam Feuerstein ✡️ (@adamfeuerstein) profile pictureAdam Feuerstein ✡️
@adamfeuersteinNov 7
And one more big CV study miss for #AHA26 Failure of Novartis $NVS Lp(a) drug raises questions about cardiovascular strategy statnews.com/2026/11/07/aha-… via @cooney_liz @matthewherper
Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

statnews.com
13
966
Buy-Side Folks: When you’ve dug into different disease areas, how well has BrandImpact reflected actual scripts or sales?
0%Closely tracked
17%Good directional
17%Rarely matched
67%Dont Ruin My Sample
12 votes • Final results
395

No more items